10 likes | 22 Views
The Non-Small Cell Lung Cancer market is expected to increase with a CAGR of 10.7% during the study period of 2017-2030.<br>The total Non-Small Cell Lung Cancer incident cases were 484,726 in 7MM in 2017.<br>Increase use of biomarker testing, increase incidence of NSCLC, increase in the mutation-specific trials activity & approval, and competitive landscape are some of the leading factors expected to drive the Non-Small Cell Lung Cancer market in the coming years.<br>The key players in Non-Small Cell Lung Cancer market include Novartis, Merck, KGaA, Eli Lilly and Company, Hoffmann-La Roche, Xcovery, BeyondSpring Pharmaceuticals, OSE Immunotherapeutics, Sanofi, Takeda, AbbVie and others.<br>For more detailed information visit: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-market<br><br><br>
E N D